Tasosartan
From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Lua error in Module:Infobox at line 314: malformed pattern (missing ']').
Tasosartan is an angiotensin II receptor antagonist.
It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.[1][2]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." />| ACE inhibitors ("-pril") |
|
|---|---|
| AIIRAs/ ("-sartan") |
|
| Renin inhibitors/ ("-kiren") |
|
|
|
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
